🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Finerenone in Patients Undergoing Transcatheter Aortic Valve Implantation With Heart Failure

RecruitingPhase 3Ages 65 Years - anyAllSecond Affiliated Hospital, Zhejiang University, …
NCT07575672 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

This study is a multicenter, double-blind, randomized, placebo-controlled trial. The purpose is to evaluate whether treatment with finerenone in patients with symptomatic severe aortic stenosis undergoing TAVI, and heart failure with LVEF ≥40% is associated with a reduction in the composite endpoint of all-cause mortality or worsening of heart failure. Participants are patients with symptomatic aortic stenosis undergoing TAVI and heart failure with LVEF≥40%. Eligible patients will be randomly assigned in a 1:1 ratio to either the finerenone group or the placebo group. Patients meeting all inclusion criteria and not any exclusion criteria will be invited to participate before discharge. All enrolled patients will consecutively receive treatment, during which serum potassium and estimated glomerular filtration rate will be closely monitored. Follow-up will be conducted at 30 days, 12 month

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: 1. Age ≥ 65 years. 2. Patients with severe aortic stenosis (aortic valve area \< 1.0 cm2 or indexed area \< 0.6 cm2/m2, or mean transvalvular aortic gradient ≥ 40 mmHg or velocity of blood flow through the valve ≥ 4.0 m/s) undergoing transfemoral TAVI. 3. New York Heart Association class ≥ II. 4. Left ventricular ejection fraction ≥ 40% at baseline prior TAVI. 5. Informed consent has been signed. Exclusion Criteria: 1. Untreated serum/plasma potassium \> 5.0 mmol/L during the screening period or randomization visit. 2. Estimated glomerular filtration rate \< 25 ml/min/1.73 m². 3. Occurred or planned to undergo: acute myocardial infarction, cardiac resynchronization therapy device implantation, stroke, or transient ischemic attack within 30 days prior to randomization. 4. Known allergy, intolerance, or contraindication to mineralocorticoid receptor antagonists. 5. Pregnant or breastfeeding patients. 6. Life expectancy \< 1 year. 7. Currently participating in a cardiovascular investigational drug or another device study and not yet completed follow-up for the primary endpoint.
💊

What it tests

  • Finerenone
  • Placebo
📍

Where

61 sites
The First Affiliated Hospital of Bengbu Medical University
Bengbu, China
The First Affiliated Hospital of University of Science and Technology of China
Hefei, China
Affiliated Beijing Chaoyang Hospital of Capital Medical University
Beijing, China
Beijing Anzhen Hospital Affiliated to Capital Medical University
Beijing, China
Chinese People's Liberation Army General Hospital
Beijing, China
Fuwai Hospital Chinese Academy of Medical Sciences
Beijing, China
Peking University Third Hospital
Beijing, China
Army Medical Center of the People's Liberation Army
Chongqing, China

…and 53 more on ClinicalTrials.gov.

🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy